Xcell Biosciences
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | - | ||
N/A | $100k | Convertible | |
N/A | N/A | Early VC | |
$5.0m | Seed | ||
$12.0m | Series A | ||
N/A | $15.5m | Late VC | |
* | $27.5m | Series B | |
* | N/A | Late VC | |
Total Funding | €54.6m |
Related Content
Recent News about Xcell Biosciences
EditXcell Biosciences, based in San Francisco, is a pioneering life science startup focused on advancing cell therapy manufacturing. The company develops cutting-edge systems that enable precise control over primary cell phenotype and function, which is crucial for optimizing the efficacy and persistence of cell therapies. Xcell Biosciences serves clients in the biotechnology and pharmaceutical sectors, particularly those involved in cell therapy research and development. Operating in the highly specialized market of cell therapy, the company employs a business model centered around the sale and licensing of its proprietary technology. Revenue is generated through direct sales of their systems, as well as through partnerships and collaborations with other biotech firms.
Keywords: cell therapy, biotechnology, pharmaceutical, primary cell control, efficacy optimization, persistence enhancement, proprietary technology, life science, startup, San Francisco.